Drug Patent List
Litigation OpportunitiesNew
Newsletter
Weekly Digest

Pharsight

Large Molecule Patents

Eylea is a drug owned by Regeneron Pharmaceuticals, Inc.. It is protect by 72 US patents. Given below is the list of those patents along with their expiration dates.

Patent Number Company Patent Title Patent Expiry Activity Alert
US10857231 REGENERON PHARMACEUTICALS, INC. Formulations of VEG antagonist fusion proteins and method of manufacturing them

()

Expired
US11525833 REGENERON PHARMACEUTICALS, INC. Hydrophobic interaction chromatography-coupled native mass spectrometry for antibody analysis
Nov, 2040

(15 years from now)

Active
US11053280 REGENERON PHARMACEUTICALS, INC. Anti-VEGF protein compositions and methods for producing the same
Aug, 2040

(15 years from now)

Active
US11104715 REGENERON PHARMACEUTICALS, INC. Methods for producing aflibercept in chemically defined media having reduced aflibercept variants
Aug, 2040

(15 years from now)

Active
US11174283 REGENERON PHARMACEUTICALS, INC. Anti-VEGF protein compositions and methods for producing the same
Aug, 2040

(15 years from now)

Active
US11186625 REGENERON PHARMACEUTICALS, INC. Anti-VEGF protein compositions and methods for producing the same
Aug, 2040

(15 years from now)

Active
US11299532 REGENERON PHARMACEUTICALS, INC. Anti-VEGF protein compositions and methods for producing the same
Aug, 2040

(15 years from now)

Active
US11306135 REGENERON PHARMACEUTICALS, INC. Anti-VEGF protein compositions and methods for producing the same
Aug, 2040

(15 years from now)

Active
US11459373 REGENERON PHARMACEUTICALS, INC. Anti-VEGF protein compositions and methods for producing the same
Aug, 2040

(15 years from now)

Active
US11459374 REGENERON PHARMACEUTICALS, INC. Anti-VEGF protein compositions and methods for producing the same
Aug, 2040

(15 years from now)

Active
US11472861 REGENERON PHARMACEUTICALS, INC. Methods for producing aflibercept in chemically defined media having reduced aflibercept variants
Aug, 2040

(15 years from now)

Active
US11485770 REGENERON PHARMACEUTICALS, INC. Anti-VEGF protein compositions and methods for producing the same
Aug, 2040

(15 years from now)

Active
US11505593 REGENERON PHARMACEUTICALS, INC. Anti-VEGF protein compositions and methods for producing the same
Aug, 2040

(15 years from now)

Active
US11535663 REGENERON PHARMACEUTICALS, INC. Methods for producing aflibercept in chemically defined media having reduced aflibercept variants
Aug, 2040

(15 years from now)

Active
US11542317 REGENERON PHARMACEUTICALS, INC. Anti-VEGF protein compositions and methods for producing the same
Aug, 2040

(15 years from now)

Active
US11548932 REGENERON PHARMACEUTICALS, INC. Anti-VEGF protein compositions and methods for producing the same
Aug, 2040

(15 years from now)

Active
US11732025 REGENERON PHARMACEUTICALS, INC. Anti-VEGF protein compositions and methods for producing the same
Aug, 2040

(15 years from now)

Active
US11753459 REGENERON PHARMACEUTICALS, INC. Anti-VEGF protein compositions and methods for producing the same
Aug, 2040

(15 years from now)

Active
US11793926 REGENERON PHARMACEUTICALS, INC. Medical device packaging and related methods
Jul, 2040

(15 years from now)

Active
US11478588 REGENERON PHARMACEUTICALS, INC. Needle shield grip devices and related methods
Jul, 2040

(15 years from now)

Active
US11439758 REGENERON PHARMACEUTICALS, INC. Devices and methods for precision dose delivery
Jun, 2040

(15 years from now)

Active
US11555176 REGENERON PHARMACEUTICALS, INC. Cell culture medium for eukaryotic cells
Jan, 2040

(15 years from now)

Active
US11850407 REGENERON PHARMACEUTICALS, INC. Needle shield grip devices and related methods
Sep, 2039

(14 years from now)

Active
US11160918 REGENERON PHARMACEUTICALS, INC. Medical device packaging and related methods
Jul, 2039

(14 years from now)

Active
US10973879 REGENERON PHARMACEUTICALS, INC. Use of a VEGF antagonist to treat angiogenic eye disorders
May, 2039

(14 years from now)

Active
US11103552 REGENERON PHARMACEUTICALS, INC. High concentration VEGF receptor fusion protein containing formulations
May, 2039

(14 years from now)

Active
US11433186 REGENERON PHARMACEUTICALS, INC. Devices and methods for precision dose delivery
Dec, 2038

(13 years from now)

Active
US11769597 REGENERON PHARMACEUTICALS, INC. Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF
Dec, 2038

(13 years from now)

Active
US11788102 REGENERON PHARMACEUTICALS, INC. CHO integration sites and uses thereof
Sep, 2038

(13 years from now)

Active
US10905786 REGENERON PHARMACEUTICALS, INC. Sterilisation method
Mar, 2038

(13 years from now)

Active
US10918754 REGENERON PHARMACEUTICALS, INC. Sterilisation method
Mar, 2038

(13 years from now)

Active
US11680930 REGENERON PHARMACEUTICALS, INC. Methods and systems for chromatography data analysis
Oct, 2037

(12 years from now)

Active
US11577025 REGENERON PHARMACEUTICALS, INC. Devices and methods for overfilling drug containers
Oct, 2037

(12 years from now)

Active
USD961376 REGENERON PHARMACEUTICALS, INC. Packaging
Aug, 2037

(12 years from now)

Active
USD961377 REGENERON PHARMACEUTICALS, INC. Packaging
Aug, 2037

(12 years from now)

Active
US10182969 REGENERON PHARMACEUTICALS, INC. Aseptic piercing system and method
Jul, 2037

(12 years from now)

Active
US11918785 REGENERON PHARMACEUTICALS, INC. Devices and methods for overfilling drug containers
Jun, 2037

(12 years from now)

Active
US10669594 REGENERON PHARMACEUTICALS, INC. Compositions and methods for detecting a biological contaminant
Feb, 2037

(12 years from now)

Active
US11549154 REGENERON PHARMACEUTICALS, INC. Compositions and methods for detecting a biological contaminant
Dec, 2036

(12 years from now)

Active
USD934069 REGENERON PHARMACEUTICALS, INC. Packaging
Oct, 2036

(11 years from now)

Active
US10927342 REGENERON PHARMACEUTICALS, INC. Taurine supplemented cell culture medium and methods of use
Aug, 2036

(11 years from now)

Active
US11312936 REGENERON PHARMACEUTICALS, INC. Taurine supplemented cell culture medium and methods of use
Aug, 2036

(11 years from now)

Active
USD906102 REGENERON PHARMACEUTICALS, INC. Packaging
Dec, 2035

(11 years from now)

Active
US11268109 REGENERON PHARMACEUTICALS, INC. CHO integration sites and uses thereof
Oct, 2035

(10 years from now)

Active
US9816110 REGENERON PHARMACEUTICALS, INC. CHO integration sites and uses thereof
Oct, 2035

(10 years from now)

Active
US9315281 REGENERON PHARMACEUTICALS, INC. System and methods for use in dispensing biopharmaceutical materials
Sep, 2034

(9 years from now)

Active
USD858754 REGENERON PHARMACEUTICALS, INC. Syringe cap
Sep, 2034

(9 years from now)

Active
US11332771 REGENERON PHARMACEUTICALS, INC. Serum-free cell culture medium
Mar, 2034

(9 years from now)

Active
US11970724 REGENERON PHARMACEUTICALS, INC. Serum-free cell culture medium
Mar, 2034

(9 years from now)

Active
US11707506 REGENERON PHARMACEUTICALS, INC. Use of a VEGF antagonist to treat angiogenic eye disorders
Jun, 2032

(7 years from now)

Active
US9254338 REGENERON PHARMACEUTICALS, INC. Use of a VEGF antagonist to treat angiogenic eye disorders
May, 2032

(7 years from now)

Active
US10130681 REGENERON PHARMACEUTICALS, INC. Use of a VEGF antagonist to treat angiogenic eye disorders
Jan, 2032

(7 years from now)

Active
US10828345 REGENERON PHARMACEUTICALS, INC. Use of a VEGF antagonist to treat angiogenic eye disorders
Jan, 2032

(7 years from now)

Active
US10857205 REGENERON PHARMACEUTICALS, INC. Use of a VEGF antagonist to treat angiogenic eye disorders
Jan, 2032

(7 years from now)

Active
US10888601 REGENERON PHARMACEUTICALS, INC. Use of a VEGF antagonist to treat angiogenic eye disorders
Jan, 2032

(7 years from now)

Active
US11253572 REGENERON PHARMACEUTICALS, INC. Use of a VEGF antagonist to treat angiogenic eye disorders
Jan, 2032

(7 years from now)

Active
US11559564 REGENERON PHARMACEUTICALS, INC. Use of a VEGF antagonist to treat angiogenic eye disorders
Jan, 2032

(7 years from now)

Active
US11975045 REGENERON PHARMACEUTICALS, INC. Use of a VEGF antagonist to treat angiogenic eye disorders
Jan, 2032

(7 years from now)

Active
US11986511 REGENERON PHARMACEUTICALS, INC. Use of a VEGF antagonist to treat angiogenic eye disorders
Jan, 2032

(7 years from now)

Active
US9669069 REGENERON PHARMACEUTICALS, INC. Use of a VEGF antagonist to treat angiogenic eye disorders
Jan, 2032

(7 years from now)

Active
US7771997 REGENERON PHARMACEUTICALS, INC. Enhanced expression and stability regions
Jul, 2028

(3 years from now)

Active
US10415055 REGENERON PHARMACEUTICALS, INC. Enhanced expression and stability regions
Jun, 2028

(3 years from now)

Active
US9222106 REGENERON PHARMACEUTICALS, INC. Enhanced expression and stability regions
Jun, 2028

(3 years from now)

Active
US9562238 REGENERON PHARMACEUTICALS, INC. Enhanced expression and stability regions
Jun, 2028

(3 years from now)

Active
US9932605 REGENERON PHARMACEUTICALS, INC. Enhanced expression and stability regions
Jun, 2028

(3 years from now)

Active
US10464992 REGENERON PHARMACEUTICALS, INC. VEGF antagonist formulations suitable for intravitreal administration
Jun, 2027

(2 years from now)

Active
US11066458 REGENERON PHARMACEUTICALS, INC. VEGF antagonist formulations suitable for intravitreal administration
Jun, 2027

(2 years from now)

Active
US11084865 REGENERON PHARMACEUTICALS, INC. VEGF antagonist formulations suitable for intravitreal administration
Jun, 2027

(2 years from now)

Active
US11732024 REGENERON PHARMACEUTICALS, INC. VEGF antagonist formulations suitable for intravitreal administration
Jun, 2027

(2 years from now)

Active
US10406226 REGENERON PHARMACEUTICALS, INC. Method of manufacturing VEGF antagonist fusion proteins
Mar, 2026

(1 year, 3 months from now)

Active
USD1035436 REGENERON PHARMACEUTICALS, INC. Packaging
Jul, 2024

(5 months ago)

Expired
US7070959 REGENERON PHARMACEUTICALS, INC. Modified chimeric polypeptides with improved pharmacokinetic properties
Jun, 2023

(1 year, 6 months ago)

Expired


Eylea's Family Patents

Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List


About Eylea

Active Ingredients:

Eylea contains Aflibercept as an active ingredient

Approval Date:

Eylea was first approved for market use on 18 Nov, 2011.

Dosage:

Eylea is available in 1 strengths and the following dosage forms are - Injection form for Intravitreal use, Injection form for Intravitreal use.

Strength Dosage Form Availability Application Pathway
2MG/0.05ML Injection Rx Intravitreal
2MG/0.05ML Injection Rx Intravitreal
2MG/0.05ML Injection Rx Intravitreal
2MG/0.05ML Injection Rx Intravitreal